Quick Answer
REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Cash And Cash Equivalents At Carrying Value of $14.44 million for the year ending 2025.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed an increase of +7.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from REVIVA PHARMACEUTICALS HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2018 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $0.00 | Q2 2018: $30.0 thousand | Q3 2018: $211.2 thousand | Q4 2018: $401.0 thousand | Q2 2019: $273.7 thousand | Q3 2019: $211.2 thousand | Q4 2019: $134.3 thousand | Q1 2020: $69.3 thousand | Q2 2020: $198.0 thousand | Q3 2020: $15.5 thousand | Q4 2020: $36.6 thousand | Q1 2021: $5.64 million | Q2 2021: $35.80 million | Q3 2021: $33.49 million | Q1 2022: $23.42 million | Q2 2022: $19.42 million | Q3 2022: $23.19 million | Q1 2023: $11.26 million | Q2 2023: $11.15 million | Q3 2023: $4.97 million | Q1 2024: $11.97 million | Q2 2024: $6.18 million | Q3 2024: $5.56 million | Q1 2025: $5.29 million | Q2 2025: $10.36 million | Q3 2025: $13.18 million.
- Historical annual values: Fiscal year 2025: $14.44 million | Fiscal year 2024: $13.48 million | Fiscal year 2023: $23.37 million | Fiscal year 2022: $18.52 million | Fiscal year 2021: $29.69 million | Fiscal year 2020: $8.76 million | Fiscal year 2020: $69.3 thousand | Fiscal year 2019: $193.00 | Fiscal year 2019: $313.0 thousand | Fiscal year 2018: $0.00.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: